Lacrimal duct obstruction

Summary

Lacrimal duct obstruction (MONDO:0001833) is a disease and 11 clinical trials. A subtype of nasolacrimal duct disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• ClinVar variants: 1
• Clinical trials: 11

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lacrimal duct obstruction
Mondo ID	MONDO:0001833
MeSH	D007767
DOID	DOID:13929
SNOMED CT	416920000
UMLS	C1281931
MedGen	226915
Is cancer (heuristic)	no

Data availability: 1 ClinVar variant.

Disease family

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye adnexa disorder › lacrimal apparatus disorder › nasolacrimal duct disorder › lacrimal duct obstruction

Related subtypes (3): acquired tear duct stenosis, dacryocystitis, nasolacrimal duct cyst

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
267843	46;XX;t(2;8)(q33.1;q24.3)dn		Uncertain significance	criteria provided, single submitter

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	10
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02636257	PHASE1/PHASE2	COMPLETED	A Comparative Study of Two Endoscopic Operations for Lacrimal Duct Obstruction
NCT07593469	Not specified	NOT_YET_RECRUITING	Outcomes of Early Lacrimal Probing Versus Lacrimal Sac Massage in Infants With Congenital Nasolacrimal Duct Obstruction
NCT00571129	Not specified	UNKNOWN	Endoscopic Dacryocystorhinostomy Prospective Research
NCT01826734	Not specified	COMPLETED	Analysis of 86 Dacryoliths at the University Hospital Ostrava
NCT02851641	Not specified	COMPLETED	Risk and Importance of Peroperative Nasal Hemorrhage in the Treatment of Lacrimal Duct Obstruction in Young Children
NCT03411889	Not specified	COMPLETED	A Feasibility Study to Develop a Protocol for Functional Lacrimal Magnetic Resonance Imaging
NCT03960996	Not specified	COMPLETED	Long Term Effectiveness of Dacryocystorinostomy With and Without Bicanalicular Intubation
NCT04931186	Not specified	COMPLETED	Nasolacrimal Duct Obstruction
NCT04943055	Not specified	UNKNOWN	Low Temperature Plasma Ablation Combined Lacrimal Duct Catheterization in the Treatment of Lacrimal Duct Obstructive
NCT05999058	Not specified	COMPLETED	Clinical Study of Lacrimal Drainage Obstruction Diseases Using Dacryoendoscopy
NCT06428266	Not specified	COMPLETED	Closed Dacryointubation vs Bicanalicular Intubation for Proximal Tear Duct Obstruction